scholarly journals CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development

2021 ◽  
Vol 11 (4) ◽  
pp. 260
Author(s):  
Eyal Sagiv ◽  
Michael A. Portman
Keyword(s):  
Drug Development ◽  
Immune Modulation ◽  
Relevant Literature ◽  
Surface Marker ◽  
Cardiovascular Research ◽  
Stem Cell Maintenance ◽  
The Past ◽  
Heat Stable ◽  
Heat Stable Antigen ◽  
Hematopoietic Cell Lines

The study of the membrane protein, CD24, and its emerging role in major disease processes, has made a huge leap forward in the past two decades. It appears to have various key roles in oncogenesis, tumor progression and metastasis, stem cell maintenance and immune modulation. First described in the 1980s as the homologous human protein to the mouse HSA (Heat Stable Antigen), it was reported as a surface marker in developing hematopoietic cell lines. The later discovery of its overexpression in a large number of human neoplasms, lead cancer researchers to discover its various active roles in critical checkpoints during cancer development and progression. Targeting CD24 in directed drug development showed promising results in cancer treatment. More recently, the chimeric CD24-Fc protein has shown exciting results in clinical trials as a specific modulator of auto-inflammatory syndromes. This report is aimed to summarize the relevant literature on CD24 and tie it together with recent advancements in cardiovascular research. We hypothesize that CD24 is a promising focus of research in the understanding of cardiovascular disease processes and the development of novel biological therapies.

The murine heat-stable antigen: a differentiation antigen expressed in both the hematolymplioid and neural cell lineages

1991 ◽  
Vol 21 (6) ◽  
pp. 1397-1402 ◽  
Author(s):  
Geneviève Rougon ◽  
Lesley A. Alterman ◽  
Karen Dennis ◽  
Xia-Jun Guo ◽  
Christine Kinnon
Keyword(s):  
Neural Cell ◽  
Differentiation Antigen ◽  
Cell Lineages ◽  
Heat Stable ◽  
Heat Stable Antigen ◽  
Antigen A

scholarly journals 3-Phenylcoumarins as a Privileged Scaffold in Medicinal Chemistry: The Landmarks of the Past Decade

Molecules ◽  
2021 ◽  
Vol 26 (21) ◽  
pp. 6755
Author(s):  
Maria J. Matos ◽  
Eugenio Uriarte ◽  
Lourdes Santana
Keyword(s):  
Medicinal Chemistry ◽  
Review Paper ◽  
Relevant Literature ◽  
Natural Origin ◽  
Drug Candidates ◽  
Heterocyclic Molecules ◽  
The Past ◽  
New Drug ◽  
Privileged Scaffold

3-Phenylcoumarins are a family of heterocyclic molecules that are widely used in both organic and medicinal chemistry. In this overview, research on this scaffold, since 2010, is included and discussed, focusing on aspects related to its natural origin, synthetic procedures and pharmacological applications. This review paper is based on the most relevant literature related to the role of 3-phenylcoumarins in the design of new drug candidates. The references presented in this review have been collected from multiple electronic databases, including SciFinder, Pubmed and Mendeley.

scholarly journals Cognitive Process of Psoriasis and Its Comorbidities: From Epidemiology to Genetics

2021 ◽  
Vol 12 ◽  
Author(s):  
Jing Gao ◽  
Xue Shen ◽  
Randy Ko ◽  
Cong Huang ◽  
Changbing Shen
Keyword(s):  
Drug Development ◽  
Skin Disease ◽  
Cognitive Process ◽  
Normal Population ◽  
Genetic Associations ◽  
Inflammatory Skin Disease ◽  
Novel Therapy ◽  
The Past ◽  
Genetic Components ◽  
The World

Psoriasis (PsO) is a chronic inflammatory skin disease that affects approximately 2% of the population all over the world. Comorbidities of PsO have increasingly garnered more interest in the past decades. Compared with the normal population, the incidences of comorbidities are higher among patients with PsO. In the last 20 years, researchers have focused on studying the genetic components of PsO, and genetic associations between PsO and its comorbidities were elucidated. This review provides an in-depth understanding and summarization of the connection between PsO and its comorbidities from the perspectives of epidemiology and genetics. Further understanding of PsO and its comorbidities will promote research on the pathogenesis, drug development, novel therapy methods, and personalized and precision treatment of PsO and its comorbidities.

Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice

1995 ◽  
Vol 25 (5) ◽  
pp. 1163-1167 ◽  
Author(s):  
Yi-Chong Wang ◽  
Lihua Zhu ◽  
Rebecca McHugh ◽  
Kenneth W. Sell ◽  
Periasamy Selvaraj
Keyword(s):  
Cell Proliferation ◽  
T Cell ◽  
Tumor Cells ◽  
T Cell Proliferation ◽  
Heat Stable ◽  
Heat Stable Antigen

Thematic Review of Trends in Inclusive Urban Development Studies (2000- 2020)

2021 ◽  
pp. 362-372
Author(s):  
Samuel Medayese ◽  
Hangwelani Hope Magidimisha-Chipungu ◽  
Ayobami Abayomi Popoola ◽  
Lovemore Chipungu ◽  
Bamiji Michael Adeleye
Keyword(s):  
Urban Development ◽  
Urban Space ◽  
Relevant Literature ◽  
Physical Development ◽  
City Development ◽  
The Past ◽  
Thematic Review ◽  
Definition Of ◽  
The City ◽  
Best Parameters

This study followed a chronological review of literature over the past 20 years. This was able to show relationship between inclusivity and physical development. A variety of discussions were looked into including dimension of inclusivity, definition of inclusivity, scales for measurement of inclusivity, methodology for appraising inclusivity, protagonists of inclusivity, and antagonists of inclusivity. The intricacy of the correlations between inclusive physical development and life expectations of residents are improved upon so as to show the similarities of these parameters. The analysis of the relevant literature indicated the process of enhancing the urban space and ensuring that all interest and strata of groups in the human composition are adequately cared for by employing the best parameters from the conceptualization of the city development, all the indicators of inclusiveness are well thought out.

Understanding ethical/unethical behavior in pharmaceutical companies: a literature review

2020 ◽  
Vol 14 (3) ◽  
pp. 367-394
Author(s):  
Geeta Marmat ◽  
Pooja Jain ◽  
P.N. Mishra
Keyword(s):  
Keyword Search ◽  
Ethical Issues ◽  
Relevant Literature ◽  
Theoretical Research ◽  
Future Research ◽  
Pharmaceutical Companies ◽  
Ethical Behaviour ◽  
Content Type ◽  
Unethical Behaviour ◽  
The Past

Purpose The purpose of this paper is to examine and review the available literature on ethical/unethical behaviour of pharmaceutical companies and to determine the ethical issues, unethical behaviour by analysing, summarising and categorising the factors related to these issues and unethical behaviour as were studied during the period 2008-2017. Essentially, this paper presents a critical analysis of the available literature on the subject and avenues for future research. Design/methodology/approach This paper adopted the systematic review approach to achieve the purpose of this study and examines the most relevant literature from online existing database sources, available between 2008-2017 by using the keyword search method. Then studies are categorised and summarised, using previously developed theories and frameworks, which have provided evidence to the universal consensus that ethical behavioural outcomes are dependent on the interplay of individual, organisational and environmental factors and have reordered to fulfil the purpose. Findings The findings identify that ethical issues related to pharmaceutical companies as were studied during the period 2008-2017 are drug pricing, drug safety and gift-giving. The organisational variables appeared to be the dominant cause of these ethical issues and unethical practices along with other determinants such as environmental and stakeholders. A large number of studies were in the western country context. Theoretical research has studied more comparatively empirical studies. Research limitations/implications This review provides insights for understanding the ethical issues, unethical behaviour and determinants related to these issues of pharmaceutical companies and provides insights where the literature is standing. This review only includes studies between 2008-2017, which are related to the ethical issue of pharmaceutical companies, therefore, the view is only of the past 10 years papers. This review provides gaps and insight into the source of ideas for future research and will help the researchers in guiding ethics-related information in the context of pharmaceutical companies. Practical implications This study will help the practitioners and policymakers in informing about the issues that required the urgent need to solve and will shed some light to focus and formulate strategies for successful competitive advantage. This study will help researchers who are seeking information related to ethics and ethical behaviour in pharmaceutical companies. Originality/value To the best of my knowledge, this review of understanding ethical/unethical behaviour in pharmaceutical companies of the past 10 years between 2008-2017 has not been done to date. This study is filling the gap by bringing all the information about ethics in pharmaceutical companies at one place, which works as an index of ethics-related study in this specific pharmaceutical company context.

scholarly journals ALS drug development: Reflections from the past and a way forward

2008 ◽  
Vol 5 (4) ◽  
pp. 516-527 ◽  
Author(s):  
Swati Aggarwal ◽  
Merit Cudkowicz
Keyword(s):  
Drug Development ◽  
The Past
Sign in / Sign up

Export Citation Format

Share Document